EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy

Fabio Matrone, Fabio Del Ben iD, Marcella Montico, Elena Muraro, Agostino Steffan, Roberto Bortolus, Lucia Fratino, Alessandra Donofrio, Veronica Paduano, Martina Zanchetta, Matteo Turetta, Giulia Brisotto

The Prostate · 2024

DOI: 10.1002/pros.24787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Fabio Matrone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Radiosurgery, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stereotactic body radiation therapy (SBRT) is an effective metastasis‐directed therapy for managing oligometastatic prostate cancer patients. However, it lacks reliable biomarkers for risk stratification. Circulating Tumor Cells (CTC) show promise as minimally invasive prognostic indicators. This study evaluates the prognostic value of CTC in oligorecurrent hormone‐sensitive prostate cancer (orHSPC). Methods orHSPC patients with 1‐3 nodal and/or bone metastases undergoing SBRT were enrolled ( N = 35), with a median follow‐up time of 42.1 months. CTC levels were measured at baseline (T0), 1 month (T1), and 3 months (T2) post‐SBRT using a novel metabolism‐based assay. These levels were correlated with clinical outcomes through Cox‐regression and Kaplan‐Meier analyses.

Results

Median CTC counts were 5 at T0, 8 at T1, and 5 at T2 with no significant variation over time. Multivariate analysis identified high (≥5/7.5 mL) T0 CTC counts (HR 2.9, 95% CI 1.3–6.5, p = 0.01, median DPFS 29.7 vs. 14.0 months) and having more than one metastasis (HR 3.9, 95% CI 1.8–8.6, p < 0.005, median DPFS 34.1 vs. 10.7 months) as independent predictors of distant progression‐free survival (DPFS). CTC assessment successfully stratified patients with a single metastasis (HR 3.4, 95% CI 1.1–10.2, p = 0.03, median DPFS 42.1 vs. 16.7 months), but not those with more than one metastasis. Additionally, a combined score based on CTC levels and the number of metastases effectively stratified patients.

Conclusion

The study demonstrates that hypermetabolic CTC could enhance risk stratification in orHSPC patients undergoing SBRT, particularly in patients with limited metastatic burden, potentially identifying patients with indolent disease who are suitable for tailored SBRT interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingRadiosurgeryProstatic NeoplasmsHumansMaleAgedPrognosisMiddle AgedAged, 80 and overBone NeoplasmsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

SBRTStereotactic Body Radiation Therapycirculating tumor cellsliquid biopsyoligometastatic prostate cancer

Autor:innen und Institutionen

  • Division of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Department of Cancer Research and Advanced Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Immunopathology and Cancer Biomarkers Units, Aviano, Italy.
  • Centro di Riferimento Oncologico di Aviano (CRO), Clinical Trial Office, Scientific Direction, IRCCS, Aviano, Italy.
  • Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

ORCID-Profile: Fabio Del Ben

Förderung

  • Ministero della Salute

Zitieren

APA

Matrone, F., Del Ben, F., Montico, M., Muraro, E., Steffan, A., Bortolus, R., Fratino, L., Donofrio, A., Paduano, V., Zanchetta, M., Turetta, M., & Brisotto, G. (2024). Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy. The Prostate. https://doi.org/10.1002/pros.24787

Vancouver

Matrone F, Del Ben F, Montico M, Muraro E, Steffan A, Bortolus R, et al. Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy. The Prostate. 2024. doi:10.1002/pros.24787

BibTeX
@article{Matrone2024,
  author = {Matrone, Fabio and Del Ben, Fabio and Montico, Marcella and Muraro, Elena and Steffan, Agostino and Bortolus, Roberto and Fratino, Lucia and Donofrio, Alessandra and Paduano, Veronica and Zanchetta, Martina and Turetta, Matteo and Brisotto, Giulia},
  title = {Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24787}
}
Kostenlos starten →